A carregar...
Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI–IM–MS/MS Assay
The third-generation tyrosine kinase inhibitor (TKI), osimertinib, has revolutionized the treatment of patients with non-small cell lung carcinoma with epidermal growth factor receptor (EGFR)-activating mutation, and resistant to first- and second-generation TKIs. Osimertinib is now also proposed as...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7409122/ https://ncbi.nlm.nih.gov/pubmed/32674434 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12071897 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|